Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization

Investigative Ophthalmology and Visual Science

Volumn 45, Issue 12, 2004, Pages 4583-4591

  Ljubimov, Alexander V ^a,e   Caballero, Sergio ^b   Aoki, Annette M ^a   Pinna, Lorenzo A ^c   Grant, Maria B ^b   Castellon, Raquel ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 ETHYL 2 (4 METHOXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4,5,6,7 TETRABROMOBENZOTRIAZOLE; 5,6 DICHLOROBENZIMIDAZOLE RIBOSIDE; APIGENIN; CALPHOSTIN C; CASEIN KINASE II; CHRYSIN; CKI 7; DACTINOMYCIN; EMODIN; GROWTH FACTOR; ILOMASTAT; LY 379196; MITOGEN ACTIVATED PROTEIN KINASE P38; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OXYGEN; PROTEIN KINASE INHIBITOR; QUERCETIN; UNCLASSIFIED DRUG; WORTMANNIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BASEMENT MEMBRANE; CATTLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; NERVE SPROUTING; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA CELL; RETINA NEOVASCULARIZATION; RETINOPATHY;

ANIMALS; BASEMENT MEMBRANE; CASEIN KINASE II; CATTLE; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; ENZYME INHIBITORS; HUMANS; MICE; MICE, INBRED C57BL; OXYGEN; RETINAL DISEASES; RETINAL NEOVASCULARIZATION; RETINAL VESSELS;

EID: 9444245342     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-0686     Document Type: Article

References (87)

1. Dor Y, Eli K. Ischemia-driven angiogenesis. Trends Cardiovasc Med. 1997;7:289-294.
2. Frank RN. Diabetic retinopathy. N Engl J Med. 2004;350:48-58.
3. østerby R. Basement membrane morphology in diabetes mellitus. In: Rifkin H, Porte D Jr, eds. Diabetes Mellitus. Theory and Practice. 4th ed. New York: Elsevier; 1990:220-233.
4. Grant MB, Spoerri PE, Player DW, et al. Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice. Invest Ophthalmol Vis Sci. 2000;41:2296-2302.
5. Paques M, Massin O, Gaudric A. Growth factors and diabetic retinopathy. Diabetes Metab. 1997;23:125-130.
6. Aiello LP, Hata Y. Molecular mechanisms of growth factor action in diabetic retinopathy. Curr Opin Endocrinol Diabetes. 1999;6: 146-156.
7. Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int. 2000;58(suppl 77): 113-119.
8. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81: 228-233.
9. Grant M, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes. 1986;35:416-420.
10. Sivalingam A, Kenney J, Brown GC, Benson WE, Donoso L. Basic fibroblast growth factor levels in the vitreous of patients with proliferative diabetic retinopathy. Arch Ophthalmol. 1990;108: 869-872.
11. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46(suppl 2): S26-S30.
12. Canton A, Burgos R, Hernandez C, et al. Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy. Br J Ophthalmol. 2000;84:732-735.
13. Grierson I, Heathcote L, Hiscott P, Hogg P, Briggs M, Hagan S. Hepatocyte growth factor/scatter factor in the eye. Prog Retin Eye Res. 2000;19:779-802.
14. Freyberger H, Brocker M, Yakut H, et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes. 2000;108:106-109.
15. Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularizatlon by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390-1395.
16. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1-29.
17. Schlingemann RO. Role of growth factors and the wound healing response in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2004;242:91-101.
18. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol. 2000;156:697-707.
19. Aiello LP. Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 1997;29:354-362.
20. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
21. Castellon R, Hamdi HK, Sacerio I, Aoki AM, Kenney MC, Ljubimov AV. Effects of angiogenic growth factor combinations on retinal endothelial cells. Exp Eye Res. 2002;74:523-535.
22. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci. 2003;73:563-579.
23. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. Circulation. 1995;92:11-14.
24. Gerritsen ME, Tomlinson JE, Zlot C, Ziman M, Hwang S. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br J Pharmacol. 2003;140:595-610.
25. Rakhit S, Pyne S, Pyne NJ. The platelet-derived growth factor receptor stimulation of p42/p44 mitogen-activated protein kinase in airway smooth muscle involves a G-protein-mediated tyrosine phosphorylation of Gab1. Mol Pharmacol. 2000;58:413-420.
26. Lawlor MA, Rotwein P. Coordinate control of muscle cell survival by distinct insulin-like growth factor activated signaling pathways. J Cell Biol. 2000;151:1131-1140.
27. Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32:53-64.
28. Castellon R, Caballero S, Hamdi HK, et al. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci. 2002;43:2758-2766.
29. Cotlin LF, Siddiqui MA, Simpson F, Collawn JF. Casein kinase II activity is required for transferrin receptor endocytosis. J Biol Chem. 1999;274:30550-30556.
30. Büchel KH. Inhibitors of photosynthesis. VI. Syntheses of electronegatively substituting benzimidazoles (in German). Z Naturforsch B. 1970;25:945-953.
31. Negulescu O, Bognar I, Lei J, Devarajan P, Silbiger S, Neugarten J. Estradiol reverses TGF-β1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism. Kidney Int. 2002;62: 1989-1998.
32. Xagorari A, Roussos C, Papapetropoulos A. Inhibition of LPS-stimulated pathways in macrophages by the flavonoid luteolin. Br J Pharmacol. 2002;136:1058-1064.
33. Yim H, Lee YH, Lee CH, Lee SK. Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med. 1999;65:9-13.
34. Channavajhala P, Seldin DC. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene. 2002;21: 5280-5288.
35. Sarno S, Reddy H, Meggio F, et al. Selectivity of 4,5,6,7- tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 (casein kinase-2). FEBS Lett. 2001;496:44-48.
36. Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci. 2001; 10:2200-2206.
37. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin. Altern Med Rev. 2000;5:546-552.
38. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr. 2002;22:19-34.
39. Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
40. Mino RP, Spoerri PE, Caballero S, et al. Adenosine receptor antagonists and retinal neovascularization in vivo. Invest Ophthalmol Vis Sci. 2001;42:3320-3324.
41. Caltagirone S, Rossi C, Poggi A, et al. Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer. 2000;87:595-600.
42. Bachmann M, Schlatter C. Metabolism of [14C]emodin in the rat. Xenobiotica. 1981;11:217-225.
43. Arosio B, Gagliano N, Fusaro LM, et al. Aloe-emodin quinone pretreatment reduces acute liver injury induced by carbon tetrachloride. Pharmacol Toxicol. 2000;87:229-233.
44. National Toxicology Program. NTP toxicology and carcinogenesis studies of emodin (CAS No. 518-82-1) feed studies in F344/N rats and B6C3F1 mice. Natl Taxicol Program Tech Rep Ser. 2001;493: 1-278.
45. Jahnke GD, Price CJ, Marr MC, Myers CB, George JD. Developmental toxicity evaluation of emodin in rats and mice. Birth Defects Res B. 2004;71:89-101.
46. Guerra B, Issinger OG. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis. 1999; 20:391-408.
47. Hilgard P, Huang T, Wolkoff AW, Stockert RJ. Translated Alu sequence determines nuclear localization of a novel catalytic subunit of casein kinase 2. Am J Physiol Cell Physiol. 2002;283:C472-C483.
48. Donella-Deana A, Cesaro L, Sarno S, et al. Tyrosine phosphorylation of protein kinase CK2 by Src-related tyrosine kinases correlates with increased catalytic activity. Biochem J. 2003;372:841-849.
49. Litchneld DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369:1-15.
50. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 2002;12: 226-230.
51. Pinna LA. Protein kinase CK2: a challenge to canons. J Cell Sci. 2002;115:3873-3878.
52. Pinna LA. The raison d'être of constitutively active protein kinases: the lesson of CK2. Acc Chem Res. 2003;36:378-384.
53. Unger GM, Davis AT, Slaton JW, Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets. 2004;4:77-84.
54. Filhol O, Martiel JL, Cochet C. Protein kinase CK2: a new view of an old molecular complex. EMBO Rep. 2004;5:351-355.
55. Loizou JI, El-Khamisy SF, Zlatanou A, et al. The protein kinase CK2 facilitates repair of chromosomal DNA single-strand breaks. Cell. 2004;117:17-28.
56. Ruzzene M, Penzo D, Pinna LA. Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J. 2002;364:41-47.
57. Landesman-Bollag E, Song DH, Romieu-Mourez R, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem. 2001;227:153-165.
58. Xu X, Landesman-Bollag E, Channavajhala PL, Seldin DC. Murine protein kinase CK2: gene and oncogene. Mol Cell Biochem. 1999; 191:65-74.
59. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Sonenshein GE. Protein kinase CK2 promotes aberrant activation of nuclear factor-κB, transformed phenotype, and survival of breast cancer cells. Cancer Res. 2002;62:6770-6778.
60. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J. 2003;17:349-368.
61. Pinna LA, Meggio F. Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. Prog Cell Cycle Res. 1997;3:77-97.
62. Bosc DG, Luscher B, Litchfield DW. Expression and regulation of protein kinase CK2 during the cell cycle. Mol Cell Biochem. 1999:191:213-222.
63. Yu S, Wang H, Davis A, Ahmed K. Consequences of CK2 signaling to the nuclear matrix. Mol Cell Biochem. 2001;227:67-71.
64. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol Histopathol. 2001;16:573-582.
65. Stepanova V, Jerke U, Sagach V, et al. Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2. J Biol Chem. 2002;277:10265-10272.
66. Faust M, Jung M, Gunther J, Zimmermann R, Montenarh M. Localization of individual subunits of protein kinase CK2 to the endoplasmic reticulum and to the Golgi apparatus. Mol Cell Biochem. 2001;227:73-80.
67. Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC. Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem. 2000;275:22245-22254.
68. Filhol O, Nueda A, Martel V, et al. Live-cell fluorescence imaging reveals the dynamics of protein kinase CK2 individual subunits. Mol Cell Biol. 2003;23:975-987.
69. Kusk M, Ahmed R, Thomsen B, Bendixen C, Issinger OG, Boldyreff B. Interactions of protein kinase CK2β subunit within the holoenzyme and with other proteins. Mol Cell Biochem. 1999;191:51-58.
70. Ruzzene M, Di Maira G, Salvi M, Arrigoni G, Pinna LA. Signalling events affected by down-regulation of protein kinase CK2. 4th International Conference on Protein Kinase CK2, London, Canada. 2004:Abstract 10.
71. Bonnet H, Filhol O, Truchet I, et al. Fibroblast growth factor-2 binds to the regulatory β subunit of CK2 and directly stimulates CK2 activity toward nucleolin. J Biol Chem. 1996;271:24781-24787.
72. Bailly K, Soulet F, Leroy D, Amalric F, Bouche G. Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB J. 2000;14:333-344.
73. Higashi K, Ogawara H. Daidzein inhibits insulin- or insulin-like growth factor-1-mediated signaling in cell cycle progression of Swiss 3T3 cells. Biochim Biophys Acta. 1994;1221:29-35.
74. Ankrapp DP, Jones JI, Clemmons DR. Characterization of insulin-like growth factor binding protein-1 kinases from human hepatoma cells. J Cell Biochem. 1996;60:387-399.
75. Coverley JA, Martin JL, Baxter RC. The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology. 2000;141:564-570.
76. Miyata Y, Nishida E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol Cell Biol. 2004;24:4065-4074.
77. Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K. A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem. 2001; 276:5992-5999.
78. Yi J, Yang J, He R, et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res. 2004;64:108-116.
79. Shieh DE, Chen YY, Yen MH, Chiang LC, Lin CC. Emodin-induced apoptosis through p53-dependent pathway in human hepatoma cells. Life Sci. 2004;74:2279-2290.
80. Chen YC, Shen SC, Lee WR, et al. Emodin induces apoptosis in human promyeloleukemic HL-60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem Pharmacol. 2002;64:1713-1724.
81. de Juan E Jr, Humayun MS, Hatchell DL, Wilson D. Histopathology of experimental preretinal neovascularization. Invest Ophthalmol Vis Sci. 1989:30:1495-1503.
82. 3H-thymidine uptake in retinal venular and capillary endothelial cells in vivo. Invest Ophthalmol Vis Sci. 1990;31: 1238-1244.
83. Chan-Ling T, Gock B, Stone J. The effect of oxygen on vasoformative cell division. Evidence that "physiological hypoxia" is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci. 1995;36:1201-1214.
84. McLeod DS, Crone SN, Lutty GA. Vasoproliferation in the neonatal dog model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1996;37:1322-1333.
85. Tan WF, Lin LP, Li MH, et al. Quercetin, a dietary-derived flavonoid, possesses antiangiogenic potential. Eur J Pharmacol. 2003;459:255-262.
86. Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001;171:11-16.
87. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.